8 results on '"Gulley, James L."'
Search Results
2. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
- Author
-
Madan, Ravi A, Antonarakis, Emmanuel S, Drake, Charles G, Fong, Lawrence, Yu, Evan Y, McNeel, Douglas G, Lin, Daniel W, Chang, Nancy N, Sheikh, Nadeem A, Gulley, James L, and Antonarakis, Emmanual S
- Subjects
IMMUNE checkpoint inhibitors ,PROSTATE-specific antigen ,CASTRATION-resistant prostate cancer ,BIOCHEMICAL mechanism of action ,ABIRATERONE acetate ,IMMUNOLOGIC memory ,ACID phosphatase ,PROSTATE tumors treatment ,RESEARCH ,CLINICAL trials ,RESEARCH methodology ,EVALUATION research ,MEDICAL cooperation ,COMPARATIVE studies ,IMPACT of Event Scale ,CANCER vaccines ,TISSUE extracts ,PROSTATE tumors - Abstract
Sipuleucel-T is an autologous cellular immunotherapy that induces an immune response targeted against prostatic acid phosphatase (PAP) to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. In the phase III IMPACT study, sipuleucel-T was associated with a statistically significantly increased overall survival (OS) (median = 4.1 months) vs placebo. Patients with baseline prostate-specific antigen levels in the lowest quartile (≤22.1 ng/mL) exhibited a 13-month improvement in OS with sipuleucel-T. Together, this led sipuleucel-T to be approved and recommended as first-line therapy in various guidelines for treatment of metastatic castration-resistant prostate cancer. This review discusses the varied findings about the mechanisms of action of sipuleucel-T, bringing them together to form a more coherent picture. These pieces include inducing a statistically significant increase in antigen-presenting cell activation; inducing a peripheral immune response specific to the target (PAP) and/or immunizing (PA2024) antigens; stimulating systemic cytotoxic T-lymphocyte activity; and mediating antigen spread (ie, increased antibody responses to secondary proteins in addition to PAP and PA2024). Each of these pieces individually correlates with OS. Sipuleucel-T also traffics T cells to the prostate and is associated with long-term immune memory such that a second course of treatment induces an anamnestic immune response. Prostate cancer does not have a strongly inflamed microenvironment, thus its response to immune checkpoint inhibitors is limited. Because sipuleucel-T is able to traffic T cells to the tumor, it may be an ideal combination partner with immunotherapies including immune checkpoint inhibitors or with radiation therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. Exploiting synergy: immune-based combinations in the treatment of prostate cancer.
- Author
-
Burotto, Mauricio, R. Heery, Christopher, Gulley, James L., Madan, Ravi A., and Singh, Nishith
- Subjects
PROSTATE cancer treatment ,IMMUNOTHERAPY ,CANCER vaccines ,PROSTATE-specific antigen ,TUMOR markers ,VACCINES ,THERAPEUTICS - Abstract
Cancer treatment is being revolutionized by the emergence of immunotherapies such as immune checkpoint inhibitors and therapeutic cancer vaccines. Prostate cancer is amenable to such therapeutic approaches. The improved understanding of the relationship between the immune system and tumors has allowed therapeutic targeting of immune checkpoints and tumor associated antigens to be developed. Furthermore, interventions used in prostate cancer are capable of impacting the immune system. As demonstrated by preclinical data and emerging clinical data, radiation therapy, anti-androgen therapy, and chemotherapy can be used with immunotherapies to obtain synergistic results. Current and future clinical trials will further investigate these principles as immunotherapeutics are combined with each other and standard therapies for optimal clinical utility. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling Time.
- Author
-
Arlen, Philip M., Bianco, Fernando, Dahut, William L., D'Amico, Anthony, Figg, William D., Freedland, Stephen J., Gulley, James L., Kantoff, Philip W., Kattan, Michael W., Lee, Andrew, Regan, Meredith M., and Sartor, Oliver
- Subjects
PROSTATE cancer ,MALE reproductive organs ,CANCER patients ,CANCER treatment - Abstract
Purpose: Prostate specific antigen is a glycoprotein found almost exclusively in normal and neoplastic prostate cells. Prostate specific antigen doubling time, or the change in prostate specific antigen over time, has emerged as a useful predictive marker for assessing disease outcome in patients with prostate cancer. It is important to agree on definitions and values for the calculation of prostate specific antigen doubling time, and to develop a common approach to outcome analysis and reporting. Materials and Methods: In September 2006 a conference was held at the National Cancer Institute in Bethesda, Maryland to define these parameters and develop guidelines for their use. Results: The Prostate Specific Antigen Working Group defined criteria regarding prostate specific antigen doubling time including the calculation of prostate specific antigen doubling time, evidence to support prostate specific antigen doubling time as a predictive factor in the setting of biochemical recurrence and the use of prostate specific antigen doubling time as a stratification factor in clinical trials. Conclusions: We propose that investigators calculate prostate specific antigen doubling time before enrolling patients in clinical studies and calculate it as an additional measurement of therapeutic activity. We believe we have developed practical guidelines for the calculation of prostate specific antigen doubling time and its use as a measurement of prognosis and outcome. Furthermore, the use of common standards for prostate specific antigen doubling time in clinical trials is important as we determine which treatments should progress to randomized trials in which “hard” end points such as survival will be used. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
5. Clinical Safety of a Viral Vector Based Prostate Cancer Vaccine Strategy.
- Author
-
Arlen, Philip M., Skarupa, Lisa, Pazdur, Mary, Seetharam, Mahesh, Tsang, Kwong Y., Grosenbach, Douglas W., Feldman, Jarett, Poole, Diane J., Litzinger, Mary, Steinberg, Seth M., Jones, Elizabeth, Chen, Clara, Marte, Jennifer, Parnes, Howard, Wright, John, Dahut, William, Schlom, Jeffrey, and Gulley, James L.
- Subjects
PROSTATE cancer ,GRANULOCYTE-macrophage colony-stimulating factor ,MALE reproductive organs ,CANCER patients - Abstract
Purpose: The primary objective of this phase I study was to evaluate the clinical safety of a vaccine using recombinant vaccinia virus (prime) and recombinant fowlpox virus (boost) in combination with granulocyte-macrophage colony-stimulating factor in patients with prostate cancer. The vaccines contained transgenes for prostate specific antigen, a triad of co-stimulatory molecules and a tumor antigen whose amino acid sequence had been modified to enhance its immunogenicity. Secondary end points were immunological and clinical responses, changes in prostate specific antigen velocity, and the kinetics of vaccinia virus clearance from the vaccination site, serum, peripheral blood mononuclear cells, urine and saliva. Materials and Methods: The 15 patients enrolled in this study had metastatic prostate cancer. Patients were given recombinant fowlpox-prostate specific antigen/triad of co-stimulatory molecules alone or recombinant vaccinia-prostate specific antigen/triad of co-stimulatory molecules followed by recombinant fowlpox-prostate specific antigen/triad of co-stimulatory molecules on a prime and boost schedule with or without recombinant-granulocyte-macrophage colony-stimulating factor protein or recombinant fowlpox-granulocyte-macrophage colony-stimulating factor vector. Prostate specific antigen specific immune responses were measured using an enzyme-linked immunosorbent spot assay for interferon-gamma production. Polymerase chain reaction for vaccinia DNA and a plaque assay for live virus were also used. Results: Some grade 2 toxicity was seen in patients who received a higher dose of recombinant fowlpox-granulocyte-macrophage colony-stimulating factor but no toxicity exceeded grade 2. Viable vaccinia was detected after vaccination at the site swab of 1 of 4 patients analyzed. Prostate specific antigen specific immune responses were seen in 4 of 6 patients who were HLA-A2+ and decreases in serum prostate specific antigen velocity were observed in 9 of 15. Conclusions: Based on the safety and preliminary immunogenicity results of this trial we recommend initiating a randomized, phase II study of prostate specific antigen/triad of co-stimulatory molecules vaccines in patients with less advanced prostate cancer. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
6. Radium-223 in prostate cancer: emitting the right signals.
- Author
-
Madan, Ravi A, Gulley, James L, and Dahut, William L
- Subjects
- *
RADIUM , *PROSTATE cancer , *PROSTATE-specific antigen , *RADIOISOTOPES , *RADIOPHARMACEUTICALS , *BONE tumors , *PROSTATE tumors - Published
- 2016
- Full Text
- View/download PDF
7. Enhancing efficacy of therapeutic vaccinations by combination with other modalities
- Author
-
Gulley, James L., Madan, Ravi A., and Arlen, Philip M.
- Subjects
- *
CANCER treatment , *CANCER endocrinology , *PREVENTIVE medicine , *HORMONE therapy - Abstract
Abstract: Novel strategies are emerging from preclinical and clinical investigations for combining vaccines with conventional and experimental anticancer therapies. Several lines of research show that combining either radiation or certain chemotherapeutic agents with vaccine can alter the phenotype of tumor cells, rendering them more susceptible to T cell-mediated killing. Furthermore, there is emerging data suggesting that an immune response elicited by vaccine may augment the antitumor effectiveness of subsequent therapies. This article reviews and discusses therapeutic cancer strategies that employ vaccines sequentially or in combination with conventional cytotoxic therapies such as local radiation, chemotherapy, and hormone therapy, or immunopotentiating therapies such as anti-CTLA-4 monoclonal antibodies. Preliminary results of clinical studies using these combination strategies have demonstrated a postvaccination antigen cascade, prolonged time to disease progression, and preliminary evidence of improved overall survival. Large randomized studies are currently underway to further investigate these findings. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
8. A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: ECOG 9802.
- Author
-
DiPaola, Robert S., Chen, Yu-Hui, Bubley, Glenn J., Stein, Mark N., Hahn, Noah M., Carducci, Michael A., Lattime, Edmund C., Gulley, James L., Arlen, Philip M., Butterfield, Lisa H., and Wilding, George
- Subjects
- *
PROSTATE cancer patients , *PROSTATE cancer treatment , *VIRAL vaccines , *CLINICAL trials , *PROSTATE-specific antigen , *POXVIRUSES , *ABLATION techniques , *VACCINES - Abstract
Background E9802 was a phase 2 multi-institution study conducted to evaluate the safety and effectiveness of vaccinia and fowlpox prostate-specific antigen (PSA) vaccine (step 1) followed by combination with androgen ablation therapy (step 2) in patients with PSA progression without visible metastasis. Objective To test the hypothesis that vaccine therapy in this early disease setting will be safe and have a biochemical effect that would support future studies of immunotherapy in patients with minimal disease burden. Design, setting, and participants Patients who had PSA progression following local therapy were treated with PROSTVAC-V (vaccinia)/TRICOM on cycle 1 followed by PROSTVAC-F (fowlpox)/TRICOM for subsequent cycles in combination with granulocyte-macrophage colony-stimulating factor (step 1). Androgen ablation was added on progression (step 2). Outcome measurements and statistical analysis Step 1 primary end points included progression at 6 mo and characterization of change in PSA velocity pretreatment to post-treatment. Step 2 end points included PSA response with combined vaccine and androgen ablation. Results and limitations In step 1, 25 of 40 eligible patients (63%) were progression free at 6 mo after registration (90% confidence interval [CI], 48–75). The median pretreatment PSA velocity was 0.13 log(PSA)/mo, in contrast to median postregistration velocity of 0.09 log(PSA)/mo ( p = 0.02), which is an increase in median PSA doubling time from 5.3 mo to 7.7 mo. No grade ≥4 treatment-related toxicity was observed. In the 27 patients eligible and treated for step 2, 20 patients achieved a complete response (CR) at 7 mo (CR rate: 74%; 90% CI, 57–87). Although supportive of larger studies in the cooperative group setting, this study is limited by the small number of patients and the absence of a control group as in a phase 3 study. Conclusions A viral PSA vaccine can be administered safely in the multi-institutional cooperative group setting to patients with minimal disease volume alone and combined with androgen ablation, supporting the feasibility of future phase 3 studies in this population. Patient summary These data support consideration of vaccine therapy earlier in the course of prostate cancer progression with minimal disease burden in future studies of vaccine approaches in earlier stages of disease. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.